Skip to main content
Top
Published in: Familial Cancer 3/2019

Open Access 01-07-2019 | Colectomy | Short Communication

Endoscopic full thickness resection for early colon cancer in Lynch syndrome

Authors: Alexandra M. J. Langers, Jurjen J. Boonstra, James C. H. Hardwick, Jolein van der Kraan, Arantza Farina Sarasqueta, Hans F.A. Vasen

Published in: Familial Cancer | Issue 3/2019

Login to get access

Abstract

Subtotal colectomy is usually the therapy of choice in Lynch syndrome patients diagnosed with colon cancer. In patients who develop cancer after the age of 50–60 years, segmental colectomy is considered a good alternative. Although the endoscopic treatment of early colorectal cancer in non-Lynch patients has increased in the last decades, almost all patients with a Lynch syndrome-associated colorectal malignancy undergo surgery, even if the tumour is diagnosed in a (very) early stage. One of the endoscopic treatment options for early colorectal cancer is an endoscopic full thickness resection (eFTR). This treatment modality allows optimal pathological examination of the resection specimen, as a transmural resection is performed with optimal T-staging of the tumour. We report a case of a 62 year old man, diagnosed with MSH2-Lynch syndrome, who underwent successful eFTR treatment of an early (pT1) colon cancer located in the ascending colon, with no signs of recurrence 12 months after treatment. We discuss the pros and cons of endoscopic resection of early colorectal carcinoma in Lynch syndrome patients.
Literature
1.
go back to reference Vasen HF, Mecklin JP, Khan PM et al (1991) The International collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425CrossRefPubMed Vasen HF, Mecklin JP, Khan PM et al (1991) The International collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425CrossRefPubMed
2.
go back to reference Houlleberghs H, Dekker M, Lantermans H, Kleinendorst R, Dubbink HJ, Hofstra RMW, Verhoef S, Te Riele R (2016) Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants. PNAS 113(15):4128–4133CrossRefPubMedPubMedCentral Houlleberghs H, Dekker M, Lantermans H, Kleinendorst R, Dubbink HJ, Hofstra RMW, Verhoef S, Te Riele R (2016) Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants. PNAS 113(15):4128–4133CrossRefPubMedPubMedCentral
3.
go back to reference NabeelZafar S, Shah AA, Channa H, Raoof M, Wilson L, Wasif N (2018) Comparison of rates and outcomes of readmission to index vs non index hospitals after major cancer surgery. JAMA Surg 153(8):719–727CrossRef NabeelZafar S, Shah AA, Channa H, Raoof M, Wilson L, Wasif N (2018) Comparison of rates and outcomes of readmission to index vs non index hospitals after major cancer surgery. JAMA Surg 153(8):719–727CrossRef
9.
go back to reference De Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, Griffioen G, Slors JF, Nagengast FM, Kleibeuker JH, Vasen HF (2003) Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52(12):1752–1755CrossRefPubMedPubMedCentral De Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, Griffioen G, Slors JF, Nagengast FM, Kleibeuker JH, Vasen HF (2003) Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52(12):1752–1755CrossRefPubMedPubMedCentral
Metadata
Title
Endoscopic full thickness resection for early colon cancer in Lynch syndrome
Authors
Alexandra M. J. Langers
Jurjen J. Boonstra
James C. H. Hardwick
Jolein van der Kraan
Arantza Farina Sarasqueta
Hans F.A. Vasen
Publication date
01-07-2019
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2019
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-019-00132-w

Other articles of this Issue 3/2019

Familial Cancer 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine